Versant Ventures

Granite Bio is a biotechnology company that specializes in the development of novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company's primary focus is on creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological pathways associated with these diseases. By advancing innovative antibody treatments, Granite Bio aims to contribute significantly to the fields of biotechnology and pharmaceuticals, addressing critical needs in the life sciences sector.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based therapies, particularly targeting kidney diseases. The company specializes in molecular and cellular biology, chemistry, and analytical capabilities, utilizing these strengths to identify and map target opportunities within specific patient subsets affected by kidney conditions. Borealis aims to enhance the delivery mechanisms of RNA medicines to distinct cell types, thereby addressing significant unmet medical needs in the treatment of kidney diseases.

LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs aimed at treating challenging diseases by selectively eliminating harmful extracellular proteins at their source within cells. The company utilizes a unique library of molecular gates along with specialized secretion-focused assays and technologies, leveraging its deep understanding of the biology of the secretory pathway. This approach facilitates precise, rapid, and repeatable drug discovery, allowing for the potential to address a diverse array of diseases using a single therapeutic mechanism.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Nexo Therapeutics is a small molecule oncology company focused on discovering and developing innovative drugs for cancer patients who have limited therapeutic options. The company utilizes a unique platform that integrates covalent ligand discovery and chemical biology, allowing it to advance small-molecule therapies aimed at challenging and previously intractable cancer targets. By unlocking a pipeline of novel oncology treatments, Nexo Therapeutics seeks to provide medical professionals with new and effective options to improve patient outcomes in the fight against cancer.

Santa Ana Bio is a biotechnology company focused on developing precision biologics for autoimmune and inflammatory diseases. The company employs advanced technologies, including deep cell profiling, multi-omics platforms, and single-cell genomics, to create targeted therapies. By utilizing antibody engineering and sophisticated analytics, Santa Ana Bio aims to deliver personalized treatments that enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Belharra Therapeutics is a privately held drug discovery company based in the San Francisco Bay Area, with its primary laboratory and offices located in San Diego. The company is focused on developing transformative small molecule drugs to address serious diseases using its innovative photoaffinity-based chemoproteomics platform. This cutting-edge technology allows Belharra scientists to identify small molecule drug candidates that can target any binding site on any protein, regardless of its conformational state or cell type. By integrating advanced biology, medicinal chemistry, and bioinformatics with drug discovery and chemoproteomics screening, Belharra aims to deliver first-in-class medicines that have the potential to significantly improve patient outcomes.

Launchpad Therapeutics is a precision oncology company focused on developing innovative antibody-based treatments for cancer. The company specializes in creating mutant-selective antibodies designed to target specific mutations found in cancer cells. By leveraging artificial intelligence-driven programs, Launchpad Therapeutics aims to deliver novel monoclonal antibodies that offer new avenues for cancer treatment. These efforts are directed towards providing medical professionals with alternative and effective therapeutic options for patients.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

SanReno Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of therapies for kidney diseases and related conditions. Operating primarily in the People’s Republic of China, Hong Kong, Macau, Taiwan, and Singapore, the company is dedicated to advancing research and development in this therapeutic area. Formed as a joint venture between Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, SanReno Therapeutics aims to create innovative solutions that enhance the quality of life for patients suffering from kidney-related ailments.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Passage Bio, Inc. is a genetic medicines company based in Philadelphia, Pennsylvania, dedicated to developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Established in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while taking responsibility for the clinical development, regulatory processes, manufacturing, and commercialization of its product candidates. The partnership also involves research and development collaborations that support the advancement of innovative treatments for these rare disorders.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Passage Bio, Inc. is a genetic medicines company based in Philadelphia, Pennsylvania, dedicated to developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Established in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while taking responsibility for the clinical development, regulatory processes, manufacturing, and commercialization of its product candidates. The partnership also involves research and development collaborations that support the advancement of innovative treatments for these rare disorders.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Gotham Therapeutics Corp. is a biotechnology company based in New York, founded in 2017, that focuses on developing innovative treatments for patients with cancers, autoimmune disorders, and neurodegenerative diseases. The company specializes in a novel class of drugs that target the machinery of epitranscriptomics, which involves altering the activity of proteins that modify messenger ribonucleic acid (mRNA). By utilizing small molecules that inhibit the transcription of proteins through modifications to mRNA, Gotham Therapeutics aims to enhance treatment options and improve outcomes for individuals affected by serious health conditions.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2015. The company specializes in developing small-molecule therapeutics aimed at treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics focuses on innovative drug discovery programs that target serious inflammatory diseases. Its therapeutic approach involves blocking inflammasome activation and disrupting the sterile inflammation loop that leads to hepatocellular injury and cell death. The company utilizes advanced methodologies, including SiRNA-based murine models for target identification and validation, as well as a unique NASH model for in vivo screening, enabling the identification of drug candidates that can intervene throughout the disease process. As of 2018, Jecure Therapeutics operates as a subsidiary of Genentech, Inc.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Kyras Therapeutics Inc. is a biotechnology company based in New York, established in 2015. The company focuses on developing innovative drugs aimed at treating incurable cancers and developmental disorders, particularly those driven by mutations in RAS genes. These mutations are implicated in a significant proportion of various cancers, including pancreatic, colorectal, and lung cancers. By addressing these critical genetic drivers, Kyras Therapeutics aims to provide effective treatment options that can potentially cure patients facing these challenging conditions.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and marketing of small molecule pharmaceuticals, specifically targeting the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company, originally established as ChanRx Corp. in 2006, rebranded to its current name in February 2015. With its headquarters in La Jolla, California, Laguna Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from these common cardiac conditions, which can lead to serious health complications such as heart attacks and strokes.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

ForSight Labs is a company dedicated to developing innovative ophthalmic technologies aimed at improving the sight, care, and quality of life for visually impaired patients. With a focus on addressing the significant challenges posed by vision loss, including conditions like glaucoma, ForSight Labs collaborates with a team of motivated professionals, clinicians, and investors to bring new solutions to the ophthalmic community. The company recognizes the profound impact of vision impairment on individuals and society, as the number of people suffering from visual impairment is expected to increase significantly in the coming years. By driving the development and commercialization of high-impact eye care technologies, ForSight Labs aims to deliver effective treatments that enhance patient outcomes and address the substantial economic burden associated with vision loss.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

AAVLife is a gene therapy company established in 2014 and headquartered in Paris, France. The firm focuses on developing treatments for Friedreich’s Ataxia Cardiomyopathy, a serious genetic disorder that leads to progressive neurological and cardiac symptoms, often manifesting in childhood or adolescence. AAVLife's innovative research utilizes adeno-associated virus (AAV) technology to deliver a normal gene to cardiac tissue, which has shown promise in reversing heart dysfunction in preclinical mouse models. The company's efforts have included planning clinical trials and collaborating with regulatory authorities to address safety and design aspects of the studies. AAVLife aims to advance its gene therapy approach to improve cardiac health in individuals affected by this life-threatening condition, emphasizing its commitment to patient communities and the organizations that support them.

Inception Sciences, founded in 2011 and headquartered in San Diego, California, with additional research sites in Vancouver and Saint Laurent, Canada, is a drug discovery company focused on creating high-value therapies to address significant unmet medical needs. The company specializes in developing small molecule pharmaceuticals through partnerships with academic experts, translating biological insights into novel drugs. Inception Sciences' team has a strong track record in drug discovery, having contributed to the development of clinical-stage compounds for conditions such as fibrosis, asthma, and COPD at Amira Pharmaceuticals, and several high-profile drugs at Merck.

ForSight Labs is a company dedicated to developing innovative ophthalmic technologies aimed at improving the sight, care, and quality of life for visually impaired patients. With a focus on addressing the significant challenges posed by vision loss, including conditions like glaucoma, ForSight Labs collaborates with a team of motivated professionals, clinicians, and investors to bring new solutions to the ophthalmic community. The company recognizes the profound impact of vision impairment on individuals and society, as the number of people suffering from visual impairment is expected to increase significantly in the coming years. By driving the development and commercialization of high-impact eye care technologies, ForSight Labs aims to deliver effective treatments that enhance patient outcomes and address the substantial economic burden associated with vision loss.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on the discovery and development of antiviral drugs targeting chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. Founded in 2006, the company specializes in creating first-in-class oral therapeutics that inhibit the viral capsid, offering innovative treatment options both as standalone therapies and in combination with existing treatments. Novira's antiviral drugs aim to address significant limitations associated with current therapies for chronic HBV and HIV, particularly the challenges of drug resistance and the need for lifelong treatment. By employing a novel mechanism of action, Novira Therapeutics seeks to provide more effective and potentially curative solutions for these global health issues. As of December 2015, Novira operates as a subsidiary of Johnson & Johnson.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Halscion, Inc. is a medical device company based in Suwanee, Georgia, founded in 2005. The company specializes in developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. Its single-use hydrogel scaffold is administered during surgical procedures by injection at the dermal-subdermal interface of wounds. This device facilitates the migration and organization of the patient's own cells, such as fibroblasts, within the wound site, thereby promoting effective healing. Halscion's biocompatible products aim to minimize the formation of undesirable scars, including keloid and hypertrophic scars, thereby improving patient recovery and aesthetic results.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Halscion, Inc. is a medical device company based in Suwanee, Georgia, founded in 2005. The company specializes in developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. Its single-use hydrogel scaffold is administered during surgical procedures by injection at the dermal-subdermal interface of wounds. This device facilitates the migration and organization of the patient's own cells, such as fibroblasts, within the wound site, thereby promoting effective healing. Halscion's biocompatible products aim to minimize the formation of undesirable scars, including keloid and hypertrophic scars, thereby improving patient recovery and aesthetic results.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Halscion, Inc. is a medical device company based in Suwanee, Georgia, founded in 2005. The company specializes in developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. Its single-use hydrogel scaffold is administered during surgical procedures by injection at the dermal-subdermal interface of wounds. This device facilitates the migration and organization of the patient's own cells, such as fibroblasts, within the wound site, thereby promoting effective healing. Halscion's biocompatible products aim to minimize the formation of undesirable scars, including keloid and hypertrophic scars, thereby improving patient recovery and aesthetic results.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

Spiration, Inc., also known as Olympus Respiratory America, is a medical device company based in Redmond, Washington. Founded in 1999, the company specializes in the development of innovative solutions for the treatment of lung diseases and air leaks. Its flagship product, the IBV valve system, is a minimally invasive device designed to redirect airflow from affected areas of the lung to healthier regions, addressing both acute and chronic conditions such as emphysema and prolonged air leaks. Operating as a subsidiary of Olympus America Inc. since 2010, Spiration focuses on enhancing respiratory health through advanced medical technology.

PhaseRx is a Seattle-based biopharmaceutical startup focused on developing intracellular enzyme replacement therapies for inherited liver diseases using its proprietary Hybrid mRNA Technology platform. This platform enables the synthesis of missing enzymes within cells, targeting three urea cycle disorders: ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase deficiency (ASL deficiency), and argininosuccinate synthetase deficiency (ASS1 deficiency). The company was founded by industry veterans and renowned academics, attracting top-tier venture capital investments.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

ForSight Labs is a company dedicated to developing innovative ophthalmic technologies aimed at improving the sight, care, and quality of life for visually impaired patients. With a focus on addressing the significant challenges posed by vision loss, including conditions like glaucoma, ForSight Labs collaborates with a team of motivated professionals, clinicians, and investors to bring new solutions to the ophthalmic community. The company recognizes the profound impact of vision impairment on individuals and society, as the number of people suffering from visual impairment is expected to increase significantly in the coming years. By driving the development and commercialization of high-impact eye care technologies, ForSight Labs aims to deliver effective treatments that enhance patient outcomes and address the substantial economic burden associated with vision loss.

Trius Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative antibiotics aimed at treating life-threatening infections. The company has successfully completed two Phase 3 clinical trials for Tedizolid Phosphate, a second-generation oxazolidinone administered both intravenously and orally, targeting serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In response to the growing issue of bacterial resistance to existing medications, Trius is focused on developing novel therapeutics to address the challenges posed by multi-drug resistant bacterial infections. The company is supported by a management team with extensive experience in drug development and regulatory processes, contributing to its commitment to advancing anti-infective drug therapies.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Spiration, Inc., also known as Olympus Respiratory America, is a medical device company based in Redmond, Washington. Founded in 1999, the company specializes in the development of innovative solutions for the treatment of lung diseases and air leaks. Its flagship product, the IBV valve system, is a minimally invasive device designed to redirect airflow from affected areas of the lung to healthier regions, addressing both acute and chronic conditions such as emphysema and prolonged air leaks. Operating as a subsidiary of Olympus America Inc. since 2010, Spiration focuses on enhancing respiratory health through advanced medical technology.